Issued 2026-09-16 at $3.34 · now $3.34 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, PYXS has typically landed between $2.25 and $5.48 — a range of −32.8% to +64.0% from the issuance price $3.34.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,218 overlapping 1 month windows · 2021-10-08 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($3.34) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where PYXS has typically landed a month from the 2026-09-16 close of $3.34 — the range is history, not a prediction.
- now $3.34 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.25 (-2.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.73–$3.77
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.25–$5.48
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-11-26 | −79.9% | −79.9% | +0.0% |
| 2025-11-25 | −79.2% | −79.6% | +0.0% |
| 2025-11-28 | −79.0% | −79.6% | +0.0% |
| 3 best | |||
| 2024-01-18 | +151.2% | +0.0% | +157.6% |
| 2023-03-01 | +147.9% | −26.9% | +147.9% |
| 2024-01-17 | +143.0% | −5.7% | +143.0% |
1,218 overlapping windows · 2021-10-08 – 2026-09-16 · not cherry-picked
Pending catalysts
- 2027-12-06 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Dupont Jakob | director | Sale | 35,000 @ $3.06 | $107K | −47.5% of holding | −4.0% | not yet — horizon still open | 38,741 | Form 4 · filed 2 days after the trade |
| 2025-04-21 | HUMPHREY RACHEL | director | Sale | 13,896 @ $1.03 | $14K | −14.6% of holding | −1.2% | +206.4% | 81,309 | Form 4 · filed 338 days after the trade |
| 2025-04-17 | HUMPHREY RACHEL | director | Sale | 200 @ $0.97 | $194 | −0.2% of holding | +14.7% | +221.9% | 95,205 | Form 4 · filed 342 days after the trade |
| 2025-04-14 | HUMPHREY RACHEL | director | Sale | 1,400 @ $0.97 | $1K | −1.4% of holding | +7.9% | +229.5% | 95,405 | Form 4 · filed 345 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
29 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-04 | Civik Thomas | director | Award / grant | 2,503,050 | 2,503,050 | Form 4 |
| 2026-08-20 | Dupont Jakob | director | Award / grant | 46,000 | 46,000 | Form 4 |
| 2026-08-12 | Civik Thomas | director | Award / grant | 250,956 | 941,087 | Form 4 |
| 2026-06-30 | Dupont Jakob | director | Option exercise | 35,000 | 73,741 | Form 4 |
| 2026-06-30 | Dupont Jakob | director | Option exercise | 35,000 | 357,461 | Form 4 |
| 2026-03-24 | Wadhane Jitendra | officer | Award / grant | 262,635 | 262,635 | Form 4 |
| 2026-03-24 | Metzger Michael A | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | Lewis-Hall Freda C | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | Dupont Jakob | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | FLAVIN JOHN L | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | Palani Santhosh | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | HUMPHREY RACHEL | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | Cline Darren S | director | Award / grant | 45,867 | 45,867 | Form 4 |
| 2026-03-24 | Wadhane Jitendra | officer | Award / grant | 109,461 | 512,882 | Form 4 |
| 2026-02-03 | Civik Thomas | director | Award / grant | 690,131 | 690,131 | Form 4 |
| 2025-03-31 | Sullivan Lara | director | Award / grant | 918,308 | 918,308 | Form 4 |
| 2025-03-31 | Connealy Pamela Ann | director | Award / grant | 414,163 | 414,163 | Form 4 |
| 2025-03-31 | Wadhane Jitendra | officer | Award / grant | 263,782 | 263,782 | Form 4 |
| 2025-03-31 | Civik Thomas | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | Cline Darren S | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | FLAVIN JOHN L | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | Metzger Michael A | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | Palani Santhosh | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | Lewis-Hall Freda C | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | HUMPHREY RACHEL | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2025-03-31 | Dupont Jakob | director | Award / grant | 36,979 | 36,979 | Form 4 |
| 2024-12-23 | Wadhane Jitendra | officer | Award / grant | 150,000 | 150,000 | Form 4 |
| 2024-12-23 | Sullivan Lara | director | Award / grant | 1,135,000 | 1,135,000 | Form 4 |
| 2024-12-23 | Connealy Pamela Ann | director | Award / grant | 310,000 | 310,000 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.